Rational design of indoleamine 2,3-dioxygenase inhibitors.

Indoleamine 2,3-dioxygenase (IDO) is an important therapeutic target for the treatment of diseases such as cancer that involve pathological immune escape. We have used the evolutionary docking algorithm EADock to design new inhibitors of this enzyme. First, we investigated the modes of binding of all known IDO inhibitors. On the basis of the observed docked conformations, we developed a pharmacophore model, which was then used to devise new compounds to be tested for IDO inhibition. We also used a fragment-based approach to design and to optimize small organic molecule inhibitors. Both approaches yielded several new low-molecular weight inhibitor scaffolds, the most active being of nanomolar potency in an enzymatic assay. Cellular assays confirmed the potential biological relevance of four different scaffolds.

[1]  M. Beyermann,et al.  Synthesis of cyclic peptides via efficient new coupling reagents , 1993 .

[2]  R. Andersen,et al.  Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. , 2008, Journal of medicinal chemistry.

[3]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[4]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[5]  F. Hirata,et al.  Indoleamine 2,3-dioxygenase. Purification and some properties. , 1978, The Journal of biological chemistry.

[6]  Michele Parrinello,et al.  A hybrid Gaussian and plane wave density functional scheme , 1997 .

[7]  Michele Parrinello,et al.  The Iron−Sulfur Bond in Cytochrome c , 1999 .

[8]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[9]  Qian Wang,et al.  Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. , 2009, Journal of medicinal chemistry.

[10]  O. Hayaishi,et al.  Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes. , 1967, The Journal of biological chemistry.

[11]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[12]  G. Prendergast,et al.  Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.

[13]  Sarah J. Thackray,et al.  Reassessment of the reaction mechanism in the heme dioxygenases. , 2009, Journal of the American Chemical Society.

[14]  Charles L. Brooks,et al.  New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations , 2003, J. Comput. Chem..

[15]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[16]  Milton W. Taylor,et al.  Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.

[17]  G. Prendergast,et al.  Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. , 2006, Journal of medicinal chemistry.

[18]  H. Knoelker,et al.  Transition Metal-Diene Complexes in Organic Synthesis. Part 22. The Iron-Mediated Quinone Imine Cyclization: A General Route to 3- Hydroxycarbazoles. , 1995 .

[19]  Teter,et al.  Separable dual-space Gaussian pseudopotentials. , 1996, Physical review. B, Condensed matter.

[20]  V. Fokin,et al.  Efficient synthesis of 2-substituted-1,2,3-triazoles. , 2008, Organic letters.

[21]  S. Goedecker,et al.  Relativistic separable dual-space Gaussian pseudopotentials from H to Rn , 1998, cond-mat/9803286.

[22]  O. Hayaishi,et al.  2,5-Dihydro-L-phenylalanine: a competitive inhibitor of indoleamine 2,3-dioxygenase. , 1978, Biochemical and biophysical research communications.

[23]  Aurélien Grosdidier,et al.  EADock: Docking of small molecules into protein active sites with a multiobjective evolutionary optimization , 2007, Proteins.

[24]  H. Rammensee,et al.  Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? , 2009, Nature Reviews Cancer.

[25]  I. Efimov,et al.  The role of serine 167 in human indoleamine 2,3-dioxygenase: a comparison with tryptophan 2,3-dioxygenase. , 2008, Biochemistry.

[26]  Takashi Otsuki,et al.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Brian O Patrick,et al.  Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. , 2006, Journal of the American Chemical Society.

[28]  Michele Parrinello,et al.  Quickstep: Fast and accurate density functional calculations using a mixed Gaussian and plane waves approach , 2005, Comput. Phys. Commun..

[29]  Aurélien Grosdidier,et al.  Blind docking of 260 protein–ligand complexes with EADock 2.0 , 2009, J. Comput. Chem..

[30]  Judith M. LaLonde,et al.  Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. , 2008, Journal of medicinal chemistry.

[31]  J. Dawson,et al.  Heme-Containing Oxygenases. , 1996, Chemical reviews.

[32]  R. Stocker,et al.  Cytochrome b5, Not Superoxide Anion Radical, Is a Major Reductant of Indoleamine 2,3-Dioxygenase in Human Cells* , 2008, Journal of Biological Chemistry.

[33]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[34]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[35]  R. Andersen,et al.  Plectosphaeroic acids A, B, and C, indoleamine 2,3-dioxygenase inhibitors produced in culture by a marine isolate of the fungus Plectosphaerella cucumerina. , 2009, Organic letters.

[36]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[37]  F. Albericio,et al.  Advantageous applications of azabenzotriazole (triazolopyridine)-based coupling reagents to solid-phase peptide synthesis , 1994 .

[38]  Edward R Zartler,et al.  Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.

[39]  B. D. Harris,et al.  Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). , 1996, The Journal of organic chemistry.

[40]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[41]  Jorge Nocedal,et al.  On the limited memory BFGS method for large scale optimization , 1989, Math. Program..

[42]  J. Jamie,et al.  Mouse and human indoleamine 2,3-dioxygenase display some distinct biochemical and structural properties , 2008, Amino Acids.

[43]  Collin M. Stultz,et al.  Fragment Docking to Proteins with the Multi‐copy Simultaneous Search Methodology , 2006 .

[44]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[45]  R. Andersen,et al.  Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. , 2006, Biotechnology journal.

[46]  J. Soroka.  Photochemistry of hemicyanines IV: Synthesis of (±) 5,6-dihydronaphto[2,1-c]-quinolizinium salts , 1992 .

[47]  Judith M. LaLonde,et al.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. , 2008, Journal of medicinal chemistry.

[48]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[49]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[50]  R. MacGillivray,et al.  Cytochrome b 5 is a major reductant in vivo of human indoleamine 2,3‐dioxygenase expressed in yeast , 2006, FEBS letters.

[51]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[52]  M. Sono,et al.  1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. , 1991, Archives of biochemistry and biophysics.

[53]  Aurélien Grosdidier,et al.  Docking to heme proteins , 2009, J. Comput. Chem..

[54]  S. Holbeck,et al.  Update on NCI in vitro drug screen utilities. , 2004, European journal of cancer.

[55]  M. Sono,et al.  Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. , 1989, Biochemistry.

[56]  M. Correia,et al.  Structure--function relationships of rat hepatic tryptophan 2,3-dioxygenase: identification of the putative heme-ligating histidine residues. , 2001, Archives of biochemistry and biophysics.

[57]  O. Hayaishi,et al.  Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by β-carboline and indole derivatives☆ , 1984 .

[58]  J. Scaiano,et al.  Photosubstitution of 1-methoxy-4-nitronaphthalene with amine nucleophiles: dual pathways , 1987 .

[59]  K. Maruoka,et al.  Novel N-alkylation of amines with organocopper reagents , 1980 .

[60]  Minshan Chen,et al.  Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[61]  G. Prendergast,et al.  Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape , 2008, Immunological reviews.

[62]  V. Karanikas,et al.  Tumor immune escape mediated by indoleamine 2,3-dioxygenase. , 2007, Immunology letters.

[63]  J. Jamie,et al.  Structural requirements of the competitive binding site of recombinant human indoleamine 2,3-dioxygenase , 1996 .

[64]  H. Knölker,et al.  Transition Metal-Diene Complexes in Organic Synthesis, Part 22.The Iron-Mediated Quinone Imine Cyclization: A General Route to 3-Hydroxycarbazoles , 1995 .

[65]  R. Andersen,et al.  Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. , 2006, Journal of natural products.

[66]  L. A. Carpino.  1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive , 1993 .

[67]  H. Rammensee,et al.  Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. , 2008, Blood.

[68]  Burke,et al.  Generalized Gradient Approximation Made Simple. , 1996, Physical review letters.